![Xin Zhang](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Xin Zhang
Keine laufenden Positionen mehr
Karriereverlauf von Xin Zhang
Ehemalige bekannte Positionen von Xin Zhang
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Wuhan Neurophth Biotechnology Co., Ltd.
![]() Wuhan Neurophth Biotechnology Co., Ltd. BiotechnologyHealth Technology Wuhan Neurophth Biotechnology Co., Ltd. is a leading in-vivo gene therapy company for ophthalmic diseases based in Wuhan, China. The Chinese company's core product, nr082 (nfs-01), is designed to treat ND4-mediated Leber's hereditary optic neuropathy (ND4-LHON) and has been granted orphan drug designation (ODD) by the FDA and EMA. It is the first Chinese gene therapy new drug that has been granted IND approval for clinical trials by the Chinese National Medical Products Administration (NMPA) and the FDA. The company's pipeline also includes ND1-mediated LHON, autosomal dominant optic atrophy, optic nerve protection, vascular retinopathy, and other preclinical candidates. The company was founded in 2016 by Bin Li, Su Xiao, Dabo Cai, and Bin Li has been the CEO since then. | Direktor/Vorstandsmitglied | - | - |
Geschäftsführer | - | - |
Statistik
International
China | 2 |
Operativ
Director/Board Member | 1 |
Chief Operating Officer | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Wuhan Neurophth Biotechnology Co., Ltd.
![]() Wuhan Neurophth Biotechnology Co., Ltd. BiotechnologyHealth Technology Wuhan Neurophth Biotechnology Co., Ltd. is a leading in-vivo gene therapy company for ophthalmic diseases based in Wuhan, China. The Chinese company's core product, nr082 (nfs-01), is designed to treat ND4-mediated Leber's hereditary optic neuropathy (ND4-LHON) and has been granted orphan drug designation (ODD) by the FDA and EMA. It is the first Chinese gene therapy new drug that has been granted IND approval for clinical trials by the Chinese National Medical Products Administration (NMPA) and the FDA. The company's pipeline also includes ND1-mediated LHON, autosomal dominant optic atrophy, optic nerve protection, vascular retinopathy, and other preclinical candidates. The company was founded in 2016 by Bin Li, Su Xiao, Dabo Cai, and Bin Li has been the CEO since then. | Health Technology |